Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (77357)
All Articles published online
|
Sep 21, 2006 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic inplication. World J Gastroenterol 2006; 12(35): 5606-5610 [PMID: 17007011 DOI: 10.3748/wjg.v12.i35.5606] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i35/5606.htm |
| Number | Citing Articles |
| 1 |
Jiang Chen Peng, Jun Shen, Zhi Hua Ran. Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease. Journal of Digestive Diseases 2014; 15(11): 585 doi: 10.1111/1751-2980.12193
|
| 2 |
Claire Painchart, Séverine Brabant, Nicolas Duveau, Maria Nachury, Pierre Desreumaux, Julien Branche, Romain Gérard, Clémentine Lauriot Dit Prevost, Pauline Wils, Thomas Lambin, Médina Boualit, Myriam Labalette, Benjamin Pariente. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease. Digestive Diseases and Sciences 2020; 65(5): 1445 doi: 10.1007/s10620-019-05865-3
|
| 3 |
Toshimi Chiba, Mikiya Endo, Shoko Matsushita, Mika Sasaki, Shoichi Chida, Yosuke Toya, Satoshi Kasugai, Nozomi Matsuda, Shunsuke Orikasa, Yukito Abiko, Norihiko Kudara, Shuhei Oana, Masaki Endo, Kazuyuki Suzuki. Peripheral Blood CD64 Levels Decrease in Crohn’s Disease following Granulocyte and Monocyte Adsorptive Apheresis. Case Reports in Gastroenterology 2011; 5(3): 667 doi: 10.1159/000335316
|
| 4 |
Le-Ning Xue, Ke-Qun Xu, Wei Zhang, Qiang Wang, Jia Wu, Xiao-Yong Wang. Associations Between Vitamin D Receptor Polymorphisms and Susceptibility to Ulcerative Colitis and Crohnʼs Disease. Inflammatory Bowel Diseases 2013; 19(1): 54 doi: 10.1002/ibd.22966
|
| 5 |
Sarah C Davies, Tran M Nguyen, Claire E Parker, John K MacDonald, Vipul Jairath, Reena Khanna. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2019; 2019(12) doi: 10.1002/14651858.CD012804.pub2
|
| 6 |
Bingcheng Feng, Lin Lin, Lixiang Li, Xin Long, Chao Liu, Zixiao Zhao, Shiyang Li, Yanqing Li. Glucocorticoid induced group 2 innate lymphoid cell overactivation exacerbates experimental colitis. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.863034
|
| 7 |
Bram Verstockt, Clémentine Perrier, Gert De Hertogh, Jonathan Cremer, Brecht Creyns, Gert Van Assche, Marc Ferrante, Jan L. Ceuppens, Séverine Vermeire, Christine Breynaert. Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease. Frontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.02983
|
| 8 |
Andrés Sansó Sureda, Vicenç Rocamora Durán, Amparo Sapiña Camaró, Vanesa Royo Escosa, María José Bosque López. Ustekinumab en paciente con enfermedad de Crohn y psoriasis inducida por anti-TNF-α. Gastroenterología y Hepatología 2011; 34(8): 546 doi: 10.1016/j.gastrohep.2011.04.003
|
| 9 |
Anja Schulz-Kuhnt, Stefan Wirtz, Markus F. Neurath, Imke Atreya. Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.01062
|
| 10 |
Jun Gu, Gang Liu, Junjie Xing, Haihan Song, Zhongchuan Wang. Fecal bacteria from Crohn's disease patients more potently activated NOD-like receptors and Toll-like receptors in macrophages, in an IL-4-repressible fashion. Microbial Pathogenesis 2018; 121: 40 doi: 10.1016/j.micpath.2018.05.009
|
| 11 |
Sonia Ghilas, Ryan O’Keefe, Lisa Anna Mielke, Dinesh Raghu, Michael Buchert, Matthias Ernst. Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.944982
|
| 12 |
Jeanne Tung, William J. Sandborn. Pediatric Inflammatory Bowel Disease. 2008; : 403 doi: 10.1007/978-0-387-73481-1_32
|
| 13 |
Maho Ikeda, Fuminao Takeshima, Hajime Isomoto, Saburo Shikuwa, Yohei Mizuta, Yoshiyuki Ozono, Shigeru Kohno. Simvastatin Attenuates Trinitrobenzene Sulfonic Acid-Induced Colitis, but Not Oxazalone-Induced Colitis. Digestive Diseases and Sciences 2008; 53(7): 1869 doi: 10.1007/s10620-007-0102-0
|
| 14 |
Caitriona Ryan, Breck Thrash, Richard B Warren, Alan Menter. The use of ustekinumab in autoimmune disease. Expert Opinion on Biological Therapy 2010; 10(4): 587 doi: 10.1517/14712591003724670
|
| 15 |
Sam Khorrami, Daniel Ginard, Ignacio Marín-Jiménez, María Chaparro, Mónica Sierra, Mariam Aguas, Beatriz Sicilia, Valle García-Sánchez, Cristina Suarez, Albert Villoria, Carlos Taxonera, Antonio Velasco-Guardado, Javier Martínez-González, Javier P. Gisbert. Ustekinumab for the Treatment of Refractory Crohnʼs Disease. Inflammatory Bowel Diseases 2016; 22(7): 1662 doi: 10.1097/MIB.0000000000000842
|
| 16 |
John K MacDonald, Tran M Nguyen, Reena Khanna, Antje Timmer. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2016; 2016(11) doi: 10.1002/14651858.CD007572.pub3
|
| 17 |
Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples, Philippe Szapary. Ustekinumab: Lessons Learned from Targeting Interleukin‐12/23p40 in Immune‐Mediated Diseases. Annals of the New York Academy of Sciences 2009; 1182(1): 97 doi: 10.1111/j.1749-6632.2009.05070.x
|
| 18 |
Jaclyn Y. Lock, Mariaelena Caboni, Philip Strandwitz, Madeleine Morrissette, Kevin DiBona, Brian A. Joughin, Kim Lewis, Rebecca L. Carrier.
An
in vitro
intestinal model captures immunomodulatory properties of the microbiota in inflammation
. Gut Microbes 2022; 14(1) doi: 10.1080/19490976.2022.2039002
|
| 19 |
Santhosh Kumar, Brant R. Ward, Anne-Marie Irani. Future Prospects of Biologic Therapies for Immunologic Diseases. Immunology and Allergy Clinics of North America 2017; 37(2): 431 doi: 10.1016/j.iac.2017.01.013
|
| 20 |
Nair Campos, Fernando Magro, Ana Rita Castro, Joana Cabral, Pedro Rodrigues, Ricardo Silva, Rui Appelberg, Susana Rodrigues, Susana Lopes, Guilherme Macedo, Amélia Sarmento. Macrophages from IBD patients exhibit defective tumour necrosis factor-α secretion but otherwise normal or augmented pro-inflammatory responses to infection. Immunobiology 2011; 216(8): 961 doi: 10.1016/j.imbio.2011.01.002
|
| 21 |
Rebecca Faleiro, Ji Liu, Deshapriya Karunarathne, Aleksandra Edmundson, Clay Winterford, Tam Hong Nguyen, Lisa A Simms, Graham Radford‐Smith, Michelle Wykes. Crohn's disease is facilitated by a disturbance of programmed death‐1 ligand 2 on blood dendritic cells. Clinical & Translational Immunology 2019; 8(7) doi: 10.1002/cti2.1071
|
| 22 |
Murat KEKİLLİ, Alpaslan TANOĞLU, Fatih KARAAHMET, Zeynal DOĞAN, Murat CAN, Abdurrahim SAYILIR, Başak ÇAKAL, Tolga DÜZENLİ, Yavuz BEYAZIT. Midkine level may be used as a noninvasive biomarker in Crohn’s disease. TURKISH JOURNAL OF MEDICAL SCIENCES 2020; 44(2): 324 doi: 10.3906/sag-1904-167
|
| 23 |
Javier P. Gisbert, María Chaparro. Ustekinumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 2017; 40(10): 688 doi: 10.1016/j.gastrohep.2017.08.006
|
| 24 |
Laszlo Bene, Andras Falus, Noemi Baffy, Andras Kristof Fulop. Cellular and Molecular Mechanisms in the Two Major Forms of Inflammatory Bowel Disease. Pathology & Oncology Research 2011; 17(3): 463 doi: 10.1007/s12253-011-9397-4
|
| 25 |
Reena Khanna, Jan C Preiss, John K MacDonald, Antje Timmer, Antje Timmer. Cochrane Database of Systematic Reviews. 2015; doi: 10.1002/14651858.CD007572.pub2
|
| 26 |
Braden T Wong, Sangwoo Park, Lauren Kovanda, Yijie He, Kwangwook Kim, Shiyu Xu, Christopher Lingga, Monika Hejna, Emma Wall, Ravichandran Sripathy, Xunde Li, Yanhong Liu. Dietary supplementation of botanical blends enhanced performance and disease resistance of weaned pigs experimentally infected with enterotoxigenic Escherichia coli F18. Journal of Animal Science 2022; 100(12) doi: 10.1093/jas/skac353
|
| 27 |
BL Kelsall. Innate and adaptive mechanisms to control of pathological intestinal inflammation. The Journal of Pathology 2008; 214(2): 242 doi: 10.1002/path.2286
|
| 28 |
Zhenggang Jiang, Wei Xu, Kang Li, Yan Yue, Lin Xu, Fei Ye, Sidong Xiong. Remission of CVB3‐induced viral myocarditis by in vivo Th2 polarization via hydrodynamics‐based interleukin‐4 gene transfer. The Journal of Gene Medicine 2008; 10(8): 918 doi: 10.1002/jgm.1215
|
| 29 |
Kan Shida, Junko Kiyoshima‐Shibata, Rumi Kaji, Masato Nagaoka, Masanobu Nanno. Peptidoglycan from lactobacilli inhibits interleukin‐12 production by macrophages induced by Lactobacillus casei through Toll‐like receptor 2‐dependent and independent mechanisms. Immunology 2009; 128(1pt2) doi: 10.1111/j.1365-2567.2009.03095.x
|
| 30 |
Omri Wolk, Svetlana Epstein, Viktoriya Ioffe-Dahan, Shimon Ben-Shabat, Arik Dahan. New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities. Expert Opinion on Drug Delivery 2013; 10(9): 1275 doi: 10.1517/17425247.2013.800480
|
| 31 |
Yoshihiro Hirata, Sozaburo Ihara, Kazuhiko Koike. Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease. Pharmacological Research 2016; 113: 574 doi: 10.1016/j.phrs.2016.09.044
|
| 32 |
C. Ma, R. N. Fedorak, G. G. Kaplan, L. A. Dieleman, S. M. Devlin, N. Stern, K. I. Kroeker, C. H. Seow, Y. Leung, K. L. Novak, B. P. Halloran, V. W. Huang, K. Wong, P. K. Blustein, S. Ghosh, R. Panaccione. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort. Alimentary Pharmacology & Therapeutics 2017; 45(9): 1232 doi: 10.1111/apt.14016
|
| 33 |
Nina Holland, Jing Dong, Elizabeth Garnett, Nishat Shaikh, Karen Huen, Paul Harmatz, Anthony Olive, Harland S Winter, Benjamin D Gold, Stanley A Cohen, Robert N Baldassano, Barbara S Kirschner, Melvin B Heyman. Reduced Intracellular T-Helper 1 Interferon-Gamma in Blood of Newly Diagnosed Children With Crohn's Disease and Age-Related Changes in Th1/Th2 Cytokine Profiles. Pediatric Research 2008; 63(3): 257 doi: 10.1203/PDR.0b013e318163a897
|
| 34 |
Parthasarathy Chandrakesan, Ishfaq Ahmed, Anisha Chinthalapally, Pomila Singh, Shanjana Awasthi, Shrikant Anant, Shahid Umar, S. M. Payne. Distinct Compartmentalization of NF-κB Activity in Crypt and Crypt-Denuded Lamina Propria Precedes and Accompanies Hyperplasia and/or Colitis following Bacterial Infection. Infection and Immunity 2012; 80(2): 753 doi: 10.1128/IAI.06101-11
|
| 35 |
Rafael Cardoso Maciel Costa Silva, Leonardo Holanda Travassos, Fabianno Ferreira Dutra. The dichotomic role of single cytokines: Fine-tuning immune responses. Cytokine 2024; 173: 156408 doi: 10.1016/j.cyto.2023.156408
|
| 36 |
Luisa Bertin, Brigida Barberio, Alessandro Gubbiotti, Lorenzo Bertani, Francesco Costa, Linda Ceccarelli, Pierfrancesco Visaggi, Giorgia Bodini, Andrea Pasta, Renato Sablich, Maria Teresa Urbano, Antonio Ferronato, Andrea Buda, Manuela De Bona, Giulio Del Corso, Alessandro Massano, Imerio Angriman, Marco Scarpa, Fabiana Zingone, Edoardo Vincenzo Savarino. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease. Journal of Clinical Medicine 2024; 13(6): 1539 doi: 10.3390/jcm13061539
|
| 37 |
Shining Ma, Tao Jiang, Rui Jiang. Constructing tissue-specific transcriptional regulatory networks via a Markov random field. BMC Genomics 2018; 19(S10) doi: 10.1186/s12864-018-5277-6
|
| 38 |
Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet. Positioning Ustekinumab in Crohn’s Disease: From Clinical Evidence to Clinical Practice. Journal of Crohn's and Colitis 2017; 11(10): 1258 doi: 10.1093/ecco-jcc/jjx079
|
| 39 |
Mark Löwenberg, Geert D’Haens. Novel Targets for Inflammatory Bowel Disease Therapeutics. Current Gastroenterology Reports 2013; 15(2) doi: 10.1007/s11894-012-0311-3
|
| 40 |
Luiza Moraes Holst, Jonas Halfvarson, Marie Carlson, Charlotte Hedin, Robert Kruse, Carl Mårten Lindqvist, Daniel Bergemalm, Sven Almér, Francesca Bresso, Maria Ling Lundström, Dirk Repsilber, Mauro D'Amato, Åsa Keita, Henrik Hjortswang, Johan Söderholm, Johanna Sundin, Hans Törnblom, Magnus Simrén, Hans Strid, Maria K Magnusson, Lena Öhman. Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis. Clinical and Experimental Gastroenterology 2022; : 129 doi: 10.2147/CEG.S368040
|
| 41 |
Qingdong Guan, Jiguo Zhang. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/4810258
|
| 42 |
Ebrahim Eskandari-Nasab, Adel Sepanjnia, Mehdi Moghadampour, Mehdi Hadadi-fishani, Alireza Rezaeifar, Abolghasem Asadi-Saghandi, Behrooz Sadeghi-Kalani, Mahdi Dehghan Manshadi, Fatemeh Pourrajab, Hossein Pourmasoumi. Circulating levels of interleukin (IL)-12 and IL-13 in Helicobacter pylori-infected patients, and their associations with bacterial CagA and VacA virulence factors. Scandinavian Journal of Infectious Diseases 2013; 45(5): 342 doi: 10.3109/00365548.2012.737930
|
| 43 |
Stefan Harsanyi, Ida Kupcova, Lubos Danisovic, Martin Klein. Selected Biomarkers of Depression: What Are the Effects of Cytokines and Inflammation?. International Journal of Molecular Sciences 2022; 24(1): 578 doi: 10.3390/ijms24010578
|
| 44 |
Reena Khanna, Brian G Feagan. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opinion on Drug Safety 2015; 14(6): 987 doi: 10.1517/14740338.2015.1029915
|
| 45 |
Špela Konjar, Cristina Ferreira, Birte Blankenhaus, Marc Veldhoen. Intestinal Barrier Interactions with Specialized CD8 T Cells. Frontiers in Immunology 2017; 8 doi: 10.3389/fimmu.2017.01281
|
| 46 |
Nadeem O. Kaakoush, Nandan P. Deshpande, Marc R. Wilkins, Chew Gee Tan, Jose A. Burgos-Portugal, Mark J. Raftery, Andrew S. Day, Daniel A. Lemberg, Hazel Mitchell, Dipshikha Chakravortty. The Pathogenic Potential of Campylobacter concisus Strains Associated with Chronic Intestinal Diseases. PLoS ONE 2011; 6(12): e29045 doi: 10.1371/journal.pone.0029045
|
| 47 |
Reena Khanna, Nilesh Chande, Séverine Vermeire, William J. Sandborn, Claire E. Parker, Brian G. Feagan. The Next Wave of Biological Agents for the Treatment of IBD. Inflammatory Bowel Diseases 2016; 22(7): 1737 doi: 10.1097/MIB.0000000000000808
|
| 48 |
Sarah C Davies, Tran M Nguyen, Claire E Parker, Reena Khanna, Vipul Jairath, John K MacDonald. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017; doi: 10.1002/14651858.CD012804
|
| 49 |
Imke Atreya, Markus Kindermann, Stefan Wirtz. Innate lymphoid cells in intestinal cancer development. Seminars in Immunology 2019; 41: 101267 doi: 10.1016/j.smim.2019.02.001
|
| 50 |
Ishfaq Ahmed, Badal Roy, Parthasarathy Chandrakesan, Anand Venugopal, Lijun Xia, Roy Jensen, Shrikant Anant, Shahid Umar. Evidence of functional cross talk between the Notch and NF-κB pathways in nonneoplastic hyperproliferating colonic epithelium. American Journal of Physiology-Gastrointestinal and Liver Physiology 2013; 304(4): G356 doi: 10.1152/ajpgi.00372.2012
|
| 51 |
Yunpeng Hua, Yi Yang, Shaoli Sun, Stephen Iwanowycz, Caroline Westwater, Boris Reizis, Zihai Li, Bei Liu. Gut homeostasis and regulatory T cell induction depend on molecular chaperone gp96 in CD11c+ cells. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-02415-7
|
| 52 |
Joanna L Richens, Richard A Urbanowicz, Elizabeth AM Lunt, Rebecca Metcalf, Jonathan Corne, Lucy Fairclough, Paul O'Shea. Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. Respiratory Research 2009; 10(1) doi: 10.1186/1465-9921-10-29
|
| 53 |
Lu Chen, Guangcong Ruan, Yi Cheng, Ailin Yi, Dongfeng Chen, Yanling Wei. The role of Th17 cells in inflammatory bowel disease and the research progress. Frontiers in Immunology 2023; 13 doi: 10.3389/fimmu.2022.1055914
|
| 54 |
Maria Lia Scribano, Laura Cantoro, Marzia Marrollo, Rocco Cosintino, Anna Kohn. Mucosal Healing With Thalidomide in Refractory Crohn’s Disease Patients Intolerant of Anti-TNF-α Drugs. Journal of Clinical Gastroenterology 2014; 48(6): 530 doi: 10.1097/MCG.0000000000000122
|
| 55 |
Ka Yee Fung, Paul M. Nguyen, Tracy L. Putoczki. Tumor Microenvironment. Advances in Experimental Medicine and Biology 2020; 1240: 59 doi: 10.1007/978-3-030-38315-2_5
|
| 56 |
Sanjay Mukherjee, Evagelia C. Laiakis, Albert J. Fornace, Sally A. Amundson. Impact of inflammatory signaling on radiation biodosimetry: mouse model of inflammatory bowel disease. BMC Genomics 2019; 20(1) doi: 10.1186/s12864-019-5689-y
|
| 57 |
Marianna Roselli, Alberto Finamore, Silvia Nuccitelli, Paola Carnevali, Patrizia Brigidi, Beatrice Vitali, Fabio Nobili, Rita Rami, Ivana Garaguso, Elena Mengheri. Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of γδT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflammatory Bowel Diseases 2009; 15(10): 1526 doi: 10.1002/ibd.20961
|
| 58 |
David Schwartz. Anti-IL-12/23. Inflammatory Bowel Diseases 2009; 15(12): 1927 doi: 10.1002/ibd.20990
|
| 59 |
Tessa Straatmijer, Vince B. C. Biemans, Dirk Jan A. R. Moes, Frank Hoentjen, Rob ter Heine, P. W. Jeroen Maljaars, Rosaline Theeuwen, Marieke Pierik, Marjolijn Duijvestein, Andrea E. van der Meulen-de Jong. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease. Digestive Diseases and Sciences 2023; 68(6): 2647 doi: 10.1007/s10620-023-07822-7
|
| 60 |
Bi-Feng Qian, Susan L. Tonkonogy, Balfour R. Sartor. Reduced responsiveness of HLA-B27 transgenic rat cells to TGF-β and IL-10-mediated regulation of IFN-γ production. Inflammatory Bowel Diseases 2008; 14(7): 921 doi: 10.1002/ibd.20415
|
| 61 |
Holger Schäffler, Dogan Doruk Demircioglu, Daniel Kühner, Sarah Menz, Annika Bender, Ingo B. Autenrieth, Peggy Bodammer, Georg Lamprecht, Friedrich Götz, Julia-Stefanie Frick, A. J. Bäumler. NOD2 Stimulation by Staphylococcus aureus-Derived Peptidoglycan Is Boosted by Toll-Like Receptor 2 Costimulation with Lipoproteins in Dendritic Cells. Infection and Immunity 2014; 82(11): 4681 doi: 10.1128/IAI.02043-14
|
| 62 |
M. Čitar, B. Hacin, G. Tompa, M. Štempelj, I. Rogelj, J. Dolinšek, M. Narat, B. Bogovič Matijašić. Human intestinal mucosa-associated Lactobacillus and Bifidobacterium strains with probiotic properties modulate IL-10, IL-6 and IL-12 gene expression in THP-1 cells. Beneficial Microbes 2015; 6(3): 325 doi: 10.3920/BM2014.0081
|
| 63 |
Yuan Li, Tingting Xu, Yue Zhao, Hui Zhang, Zesheng Liu, Hao Wang, Chaoying Huang, Zhihao Shu, Lixin Gao, Rongrong Xie, Tingying Jiao, Dan Zhang, Dong Zhang, Xuewu Liang, Yi Zang, Yili Sun, Hong Liu, Jia Li, Yu Zhou. Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry 2024; 67(7): 5642 doi: 10.1021/acs.jmedchem.3c02304
|
| 64 |
Javier P. Gisbert, María Chaparro. Ustekinumab to treat Crohn's disease. Gastroenterología y Hepatología (English Edition) 2017; 40(10): 688 doi: 10.1016/j.gastre.2017.08.003
|
| 65 |
Qing-Feng Tang, Qing Ji, Yu Tang, Song-Jiao Hu, Yi-Jie Bao, Wen Peng, Pei-Hao Yin. Golgi Phosphoprotein 2 Down-regulates the Th1 Response in Human Gastric Cancer Cells by Suppressing IL-12A. Asian Pacific Journal of Cancer Prevention 2013; 14(10): 5747 doi: 10.7314/APJCP.2013.14.10.5747
|
| 66 |
Benno Weigmann. T-Helper Cells. Methods in Molecular Biology 2014; 1193: 143 doi: 10.1007/978-1-4939-1212-4_14
|
| 67 |
Reena Khanna, Brian G Feagan. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy 2013; 5(8): 803 doi: 10.2217/imt.13.81
|
| 68 |
William J. Sandborn, Brian G. Feagan, Richard N. Fedorak, Ellen Scherl, Mark R. Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease. Gastroenterology 2008; 135(4): 1130 doi: 10.1053/j.gastro.2008.07.014
|
| 69 |
Chiara Grazia De Ciucis, Floriana Fruscione, Livia De Paolis, Samanta Mecocci, Susanna Zinellu, Lisa Guardone, Giulia Franzoni, Katia Cappelli, Elisabetta Razzuoli. Toll-like Receptors and Cytokine Modulation by Goat Milk Extracellular Vesicles in a Model of Intestinal Inflammation. International Journal of Molecular Sciences 2023; 24(13): 11096 doi: 10.3390/ijms241311096
|
| 70 |
Jian Li, Andria L. Doty, Atif Iqbal, Sarah C. Glover. The differential frequency of Lineage−CRTH2−CD45+NKp44−CD117−CD127+ILC subset in the inflamed terminal ileum of patients with Crohn’s disease. Cellular Immunology 2016; : 63 doi: 10.1016/j.cellimm.2016.05.001
|
| 71 |
Stacey Rolak, Sunanda V. Kane. Conventional Therapies for Crohn's Disease. Gastroenterology Clinics of North America 2022; 51(2): 271 doi: 10.1016/j.gtc.2021.12.004
|
| 72 |
Karine Mariane Steigleder, Fernando Lopes Ponte Neto, Cristiane Kibune Nagasako, Raquel Franco Leal. Biological Therapy for Inflammatory Bowel Disease. 2020; doi: 10.5772/intechopen.90536
|
| 73 |
N. Maharshak, G. Hart, E. Ron, E. Zelman, A. Sagiv, N. Arber, E. Brazowski, R. Margalit, E. Elinav, I. Shachar. CCL2 (pM levels) as a therapeutic agent in inflammatory bowel disease models in mice. Inflammatory Bowel Diseases 2010; 16(9): 1496 doi: 10.1002/ibd.21254
|
| 74 |
Bo Chen, Yiqing Wang, YouYa Niu, Shenghua Li. Acalypha australis L. Extract Attenuates DSS-Induced Ulcerative Colitis in Mice by Regulating Inflammatory Factor Release and Blocking NF-κB Activation. Journal of Medicinal Food 2023; 26(9): 663 doi: 10.1089/jmf.2023.K.0037
|
| 75 |
Farzana Rashid, Gary R. Lichtenstein. Pediatric Inflammatory Bowel Disease. 2017; : 425 doi: 10.1007/978-3-319-49215-5_35
|
| 76 |
Tao Liu, Shao-Heng He, Peng-Yuan Zheng, Tao-Yuan Zhang, Bin-Quan Wang, Ping-Chang Yang. Staphylococcal enterotoxin B increases TIM4 expression in human dendritic cells that drives naïve CD4 T cells to differentiate into Th2 cells. Molecular Immunology 2007; 44(14): 3580 doi: 10.1016/j.molimm.2007.03.004
|
| 77 |
Clémentine Perrier, Paul Rutgeerts. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011; 3(11): 1341 doi: 10.2217/imt.11.122
|
| 78 |
Claudia Pena Rossi, Stephen B Hanauer, Ratko Tomasevic, John O Hunter, Ira Shafran, Hans Graffner. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterology 2009; 9(1) doi: 10.1186/1471-230X-9-22
|
| 79 |
A. A. Hotko, M. Yu. Pomazanova, M. V. Durleshter. Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis. Medical alphabet 2021; (34): 35 doi: 10.33667/2078-5631-2021-34-35-38
|
| 80 |
John H. Chidlow, Deepti Shukla, Matthew B. Grisham, Christopher G. Kevil. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. American Journal of Physiology-Gastrointestinal and Liver Physiology 2007; 293(1): G5 doi: 10.1152/ajpgi.00107.2007
|
| 81 |
P. Mansueto, G. Iacono, A. Seidita, A. D'Alcamo, D. Sprini, A. Carroccio. Review article: intestinal lymphoid nodular hyperplasia in children – the relationship to food hypersensitivity. Alimentary Pharmacology & Therapeutics 2012; 35(9): 1000 doi: 10.1111/j.1365-2036.2012.05062.x
|
| 82 |
Thanh-Huyen Tran, Mansoor M Amiji. Targeted delivery systems for biological therapies of inflammatory diseases. Expert Opinion on Drug Delivery 2015; 12(3): 393 doi: 10.1517/17425247.2015.972931
|
| 83 |
Fei Ma, Mingning Zhao, Zhenyu Song, Zhongchuan Wang. T‐bet interferes with PD‐1/PD‐L1‐mediated suppression of CD4+ T cell inflammation and survival in Crohn's disease. Clinical and Experimental Pharmacology and Physiology 2019; 46(9): 798 doi: 10.1111/1440-1681.13127
|
| 84 |
Christopher J. Lessard, Indra Adrianto, John A. Ice, Graham B. Wiley, Jennifer A. Kelly, Stuart B. Glenn, Adam J. Adler, He Li, Astrid Rasmussen, Adrienne H. Williams, Julie Ziegler, Mary E. Comeau, Miranda Marion, Benjamin E. Wakeland, Chaoying Liang, Paula S. Ramos, Kiely M. Grundahl, Caroline J. Gallant, Graciela S. Alarcón, Juan-Manuel Anaya, Sang-Cheol Bae, Susan A. Boackle, Elizabeth E. Brown, Deh-Ming Chang, Soo-Kyung Cho, Lindsey A. Criswell, Jeffrey C. Edberg, Barry I. Freedman, Gary S. Gilkeson, Chaim O. Jacob, Judith A. James, Diane L. Kamen, Robert P. Kimberly, Jae-Hoon Kim, Javier Martin, Joan T. Merrill, Timothy B. Niewold, So-Yeon Park, Michelle A. Petri, Bernardo A. Pons-Estel, Rosalind Ramsey-Goldman, John D. Reveille, R. Hal Scofield, Yeong Wook Song, Anne M. Stevens, Betty P. Tsao, Luis M. Vila, Timothy J. Vyse, Chack-Yung Yu, Joel M. Guthridge, Kenneth M. Kaufman, John B. Harley, Edward K. Wakeland, Carl D. Langefeld, Patrick M. Gaffney, Courtney G. Montgomery, Kathy L. Moser. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication Study. The American Journal of Human Genetics 2012; 90(4): 648 doi: 10.1016/j.ajhg.2012.02.023
|
| 85 |
Bruce E. Sands, Eric W. Jacobson, Thomas Sylwestrowicz, Ziad Younes, Gerald Dryden, Richard Fedorak, Susan Greenbloom. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease. Inflammatory Bowel Diseases 2010; 16(7): 1209 doi: 10.1002/ibd.21159
|
| 86 |
M. V. Shapina, B. A. Nanaeva, A. V. Vardanyan. EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (review. Koloproktologia 2019; 18(3(69)): 119 doi: 10.33878/2073-7556-2019-18-3-119-130
|
| 87 |
Wojciech Blonski, Faten Aberra, Gary R. Lichtenstein. Pediatric Inflammatory Bowel Disease. 2013; : 357 doi: 10.1007/978-1-4614-5061-0_34
|
| 88 |
Guntram A. Grassl, Yanet Valdez, Kirk S.B. Bergstrom, Bruce A. Vallance, B. Brett Finlay. Chronic Enteric Salmonella Infection in Mice Leads to Severe and Persistent Intestinal Fibrosis. Gastroenterology 2008; 134(3): 768 doi: 10.1053/j.gastro.2007.12.043
|
| 89 |
Serban Gologan, Razvan Iacob, Daniela Iancu, Speranta Iacob, Bogdan Cotruta, Roxana Vadan, Ana-Maria Catuneanu, Ileana Constantinescu, Ligia Barbarii, Cristian Gheorghe, Mircea Diculescu. Inflammatory gene expression profiles in Crohn's disease and ulcerative colitis: A comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol. Journal of Crohn's and Colitis 2013; 7(8): 622 doi: 10.1016/j.crohns.2012.08.015
|
| 90 |
Aiping Bai, Zhikang Peng. Biological therapies of inflammatory bowel disease. Immunotherapy 2010; 2(5): 727 doi: 10.2217/imt.10.51
|
| 91 |
Tiffanny N Newman, Elisabetta Liverani, Elitza Ivanova, Gian L Russo, Nick Carpino, Doina Ganea, Fayez Safadi, Satya P Kunapuli, Alexander Y Tsygankov. Members of the novel UBASH3/STS/TULA family of cellular regulators suppress T‐cell‐driven inflammatory responses in vivo. Immunology & Cell Biology 2014; 92(10): 837 doi: 10.1038/icb.2014.60
|
| 92 |
Claudia Guzy, Anja Schirbel, Daniela Paclik, Bertram Wiedenmann, Axel Dignass, Andreas Sturm. Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro. European Journal of Nutrition 2009; 48(1): 12 doi: 10.1007/s00394-008-0754-3
|
| 93 |
Kun Lv, Wei Xu, Cuini Wang, Toshiro Niki, Mitsuomi Hirashima, Sidong Xiong. Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells. Clinical Immunology 2011; 140(1): 92 doi: 10.1016/j.clim.2011.03.017
|
| 94 |
Nobuhiko Hayakawa, Masatsugu Noguchi, Sen Takeshita, Agung Eviryanti, Yukie Seki, Hikaru Nishio, Ryohei Yokoyama, Misato Noguchi, Manami Shuto, Yoichiro Shima, Kanna Kuribayashi, Shunsuke Kageyama, Hiroyuki Eda, Manabu Suzuki, Tomohisa Hatta, Shun-ichiro Iemura, Tohru Natsume, Itsuya Tanabe, Ryusuke Nakagawa, Makoto Shiozaki, Kuniya Sakurai, Masataka Shoji, Ayatoshi Andou, Takashi Yamamoto. Structure–activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201. Bioorganic & Medicinal Chemistry 2014; 22(11): 3021 doi: 10.1016/j.bmc.2014.03.036
|
| 95 |
Alexander Sotra, Kimia Asadi Jozani, Boyang Zhang. A vascularized crypt-patterned colon model for high-throughput drug screening and disease modelling. Lab on a Chip 2023; 23(15): 3370 doi: 10.1039/D3LC00211J
|
| 96 |
Kimberly A. Harris, Sara Horst, Akash Gadani, Anne Nohl, Kim Annis, Caroline Duley, Dawn Beaulieu, Leyla Ghazi, David A. Schwartz. Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab. Inflammatory Bowel Diseases 2016; 22(2): 397 doi: 10.1097/MIB.0000000000000624
|
| 97 |
R. Queiro, D. Ginard. Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-Sifiliográficas 2012; 103: 65 doi: 10.1016/S0001-7310(12)70011-X
|
| 98 |
Fernando Magro, Rosa Coelho, Armando Peixoto. Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?. Current Medicinal Chemistry 2019; 26(2): 248 doi: 10.2174/0929867325666181101114937
|